Welcome to our dedicated page for Repligen news (Ticker: RGEN), a resource for investors and traders seeking the latest updates and insights on Repligen stock.
Repligen Corporation reports business developments as a global life sciences company focused on bioprocessing technologies and systems used in manufacturing biological drugs. Its updates center on Filtration and Fluid Management, Chromatography, Process Analytics and Proteins, serving biopharmaceutical drug developers, CDMOs and other life science customers.
Recurring announcements include quarterly and annual financial results, financial guidance, organic revenue measures, margin commentary, product and support infrastructure such as Repligen Training & Innovation Centers and OPUS pre-packed chromatography columns, investor conference participation, regional customer support initiatives and board or senior finance governance changes.
Repligen (NASDAQ:RGEN) will participate in three investor conferences in March 2026: Leerink Global Healthcare (Mar 8–11), Barclays Global Healthcare (Mar 10–12) and KeyBanc Virtual Healthcare Forum (Mar 17–18). Executives Jason Garland and Olivier Loeillot will take part in analyst-led discussions on March 10–11 and March 18, with live webcasts for Leerink and KeyBanc available on the company investor relations website and replayable for a limited time.
Repligen (NASDAQ:RGEN) reported Q4 2025 revenue of $198M (up 18% reported, 14% organic) and full-year 2025 revenue of $738M (up 16% reported, 14% organic non-COVID). GAAP net income for FY2025 was $49M, adjusted net income was $97M, and cash plus marketable securities totaled $768M.
For 2026 the company guided to $810M–$840M revenue, 9%–13% organic growth, and adjusted operating margin expansion of ~150 basis points at the midpoint.
Repligen (NASDAQ:RGEN) will report fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026. A press release will be issued before market open and management will host a conference call at 8:30 a.m. ET to discuss results for periods ended December 31, 2025.
The live call is toll-free at (800) 715-9871 (U.S.) or (646) 307-1963 (international) with no passcode. A webcast and subsequent replay will be available in the company Investor Relations section of the website.
Repligen (NASDAQ: RGEN) announced that Dr. Martin D. Madaus was elected Chair of the Board effective March 13, 2026, as Executive Chair Tony Hunt retires from the Board on that date and will remain as an advisor through March 2027. Dr. Madaus has served as a Repligen director since February 2023 and brings 36 years of industry experience, including five years as Chairman, President and CEO of Millipore and involvement in its 2010 acquisition by Merck KGaA. Dr. Madaus also serves on the boards of Azenta and Hologic and holds a D.V.M. and Ph.D. from universities in Germany.
Repligen (NASDAQ:RGEN) will present at the J.P. Morgan 2026 Healthcare Conference in San Francisco, January 12–15, 2026.
Olivier Loeillot, President and CEO, will deliver an overview of the company on Tuesday, January 13 at 2:15 p.m. PT. A live webcast will be available on Repligen’s investor relations website and will be replayable for a limited period after the event.
Repligen (NASDAQ:RGEN) announced three new high-performance chromatography resins on Dec. 16, 2025: AVIPure HiPer AAV9, AVIPure HiPer AAV8 affinity resins and HiPer QA anion exchange resin. Built on Tantti DuloCore base bead technology, the convective HiPer resins target next‑generation modalities such as viral vectors and gene therapy.
The company says the resins are engineered to help gene therapy developers accelerate product development, improve molecule stability, and enhance process economics, and that the launch strengthens Repligen's proteins portfolio ahead of broader chromatography resin rollouts planned for 2026.
Repligen (NASDAQ:RGEN) will participate in the 8th Annual Evercore Healthcare Conference taking place Dec 2–4, 2025 in Coral Gables, Florida.
Jason Garland, Chief Financial Officer, will join an analyst-led discussion on Dec 3, 2025 at 1:20 p.m. ET. A live webcast will be available on Repligen’s Investor Relations website at www.repligen.com, with a limited-time replay following the event.
Repligen (NASDAQ:RGEN) will attend five investor conferences in November 2025 with executive participation and webcasts available. Key events: UBS Global Healthcare (Nov 10–12, Palm Beach Gardens; CFO Jason Garland on Nov 10 at 11:00 a.m. ET), Stifel Healthcare (Nov 11–13, New York; CEO Olivier Loeillot on Nov 11 at 10:00 a.m. ET), Wolfe Research Healthcare (Nov 17–19, New York; CFO Jason Garland on Nov 18 at 12:40 p.m. ET), Jefferies Global Healthcare (Nov 18–20, London; CEO Olivier Loeillot on Nov 18 at 8:30 a.m. ET/1:30 p.m. GMT), and Stephens Annual Investment (Nov 18–20, Nashville; CFO one-on-ones on Nov 19).
A live webcast of presentations will be available on Repligen’s Investor Relations website and replayed for a limited time.
Repligen (NASDAQ:RGEN) reported Q3 2025 revenue of $189M, up 22% reported and 18% organic year‑over‑year, and raised full‑year revenue guidance to $729M–$737M. The company said all franchises and geographies posted double‑digit growth, consumables and capital equipment grew >20%, and Process Analytics equipment placements hit a record quarter after the SoloVPE PLUS launch.
Q3 GAAP net income was $15M and adjusted net income was $26M; GAAP EPS was $0.26 and adjusted EPS was $0.46. Cash and cash equivalents were $749M at Sept 30, 2025. FY2025 adjusted guidance includes organic, non‑COVID growth of 14%–15.5%, adjusted operating income of $98M–$100M, and adjusted EPS of $1.65–$1.68.
Repligen (NASDAQ:RGEN) will report its third quarter 2025 financial results on Tuesday, October 28, 2025. A press release will be issued before the market opens, followed by a conference call at 8:30 a.m. ET to discuss business updates and results for the three- and nine-month periods ended September 30, 2025.
The live call is accessible toll-free at (800) 715-9871 (U.S.) or (646) 307-1963 (international) with no passcode required. A webcast will be available and archived via the company Investor Relations website, and a replay will be posted after the event.